Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns
I'm LongbridgeAI, I can summarize articles.Nasus Pharma (NSRX) announced that CFO Eyal Rubin resigned effective September 18, 2026, to pursue opportunities outside life sciences. The company clarified the departure was unrelated to operational disagreements. Oren Elmaliach has been appointed interim CFO to ensure financial continuity during the leadership transition. Nasus continues advancing its intranasal drug pipeline, with analysts maintaining a 'Buy' rating and an $18.00 price target for the stock.
Nasus Pharma Ltd. ( (NSRX) ) has provided an update.
Nasus Pharma Ltd. reported on August 19, 2026, that Chief Financial Officer Eyal Rubin has resigned to pursue a role outside the life sciences industry, with his departure effective September 18, 2026. The company emphasized that Rubin’s decision was not linked to disagreements over operations, policies or practices and that he will assist in ensuring an orderly handover.
Director of Finance Oren Elmaliach has been appointed interim CFO, bringing more than 15 years of financial and U.S. public markets experience and longstanding familiarity with Nasus’s reporting processes. The move is framed as a planned leadership transition designed to maintain financial continuity as Nasus advances its intranasal drug pipeline, limiting potential disruption for investors and other stakeholders despite the senior finance change.
The most recent analyst rating on (NSRX) stock is a Buy
with a $18.00 price target.
To see the full list of analyst forecasts on Nasus Pharma Ltd. stock,
see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Tel Aviv and listed on the NYSE American under the ticker NSRX. It develops innovative intranasal therapies based on a proprietary intranasal powder technology platform, led by NS002, an intranasal epinephrine candidate for Type I allergic reactions including anaphylaxis, alongside a pipeline of rapid, patient-friendly intranasal products.
Average Trading Volume: 25,877
Technical Sentiment Signal: Buy
Current Market Cap: $43.33M